 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12...113114115116117118119120121122123...229230» |
- | Journal, IO biomarker: TLR4 promotes microglial pyroptosis via lncRNA-F630028O10Rik by activating PI3K/AKT pathway after spinal cord injury. (Pubmed Central) - Apr 21, 2021
Furthermore, we determined STAT1 was the upstream transcriptional factor of IncRNA-F630028O10Rik and was induced by the damage-responsive TLR4/MyD88 signal. Our findings provide new insights and a novel therapeutic strategy for treating SCI.
- || Retrospective data, Review, Journal: Worldwide Prevalence of PI3K-AKT-mTOR Pathway Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Apr 21, 2021
No associations were found between alcohol and tobacco exposure, and tumor differentiation grade. This SR demonstrated that the PI3K-AKT-mTOR pathway emerges as a potential prognostic factor and could offer a molecular basis for future studies on therapeutic targeting in HNC patients.
- || Clinical, Journal: Construction of N-Boc-2-Alkylaminoquinazolin-4(3H)-Ones via a Three-Component, One-Pot Protocol Mediated by Copper(II) Chloride that Spares Enantiomeric Purity. (Pubmed Central) - Apr 21, 2021
Copper(II) chloride was essential to retaining enantiopurity, and reaction component structural changes were well tolerated, resulting in an efficient, all-in-one procedure that promotes sequential coupling, lactonization, aminolysis, and cyclization in good yields. The method was applied to the rapid assembly of four key intermediates used in the synthesis of high profile quinazolinones, including several PI3K inhibitor drugs.
- | Journal: Proteome Analysis of USP7 Substrates Revealed Its Role in Melanoma Through PI3K/Akt/FOXO and AMPK Pathways. (Pubmed Central) - Apr 21, 2021
The results showed that inhibition of USP7 increases expression of the AMPK beta (PRKAB1), caspase 7(CASP7), and protein phosphatase 2 subunit B R3 isoform (PPP2R3A), while attenuating expression of C subunit of vacuolar ATPase (ATP6V0C), and peroxisomal biogenesis factor 11 beta (PEX11B). In summary, these findings reveal an important role of USP7 in regulating melanoma progression via PI3K/Akt/FOXO and AMPK signaling pathways and implicate USP7 as an attractive anticancer target for melanoma.
- | Journal: MicroRNA-218 regulates the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting BMI-1. (Pubmed Central) - Apr 21, 2021
The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/19014.
- || Aliqopa (copanlisib) / Bayer
Clinical, Journal: Long-term safety and efficacy of the PI3K- inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. (Pubmed Central) - Apr 20, 2021
TEAEs showed no evidence for increased incidence or worsening following longer exposure in patients treated >1 year. Long-term follow-up of patients with relapsed/refractory indolent B-cell lymphoma treated with intravenous copanlisib demonstrated durable, enhanced responses without evidence of worsening TEAEs, as reported for orally administered PI3K inhibitors.
- | Journal: Ubiquitous macropinocytosis in anthozoans. (Pubmed Central) - Apr 20, 2021
Furthermore, we reveal that macropinocytosis is likely a major endocytic pathway in other anthozoan species. The fact that nearly all cells of an animal are continuously soaking in the environment challenges many aspects of the classical physiology viewpoints acquired from the study of bilaterians.
- | Preclinical, Journal: Anti-allergic function of α-Tocopherol is mediated by suppression of PI3K-PKB activity in mast cells in mouse model of allergic rhinitis. (Pubmed Central) - Apr 20, 2021
The fact that nearly all cells of an animal are continuously soaking in the environment challenges many aspects of the classical physiology viewpoints acquired from the study of bilaterians. Our results demonstrated that α-TCP-mediated suppression of PI3K-PKB activity in mast cells is a potential mechanism of anti-allergic function of α-TCP.
- | Journal: Exogenous hydrogen sulfide reduces atrial remodeling and atrial fibrillation induced by diabetes mellitus via activation of the PI3K/Akt/eNOS pathway. (Pubmed Central) - Apr 20, 2021
In summary, DM status can lead to the structural remodeling of atrial fibrosis, facilitating AF incidence and persistence. Administration of H2S does not affect the glucose level, but can significantly mitigate atrial fibrosis and reduce the incidence of AF induced by DM, probably via activation of the PI3K/Akt/eNOS pathway.
- | Journal: microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis. (Pubmed Central) - Apr 20, 2021
Administration of H2S does not affect the glucose level, but can significantly mitigate atrial fibrosis and reduce the incidence of AF induced by DM, probably via activation of the PI3K/Akt/eNOS pathway. Our study proposed and demonstrated that miR-451a downregulation mediated by DNMT3B is critical for proliferation, migration, and invasion of BCa, which may be beneficial for developing more effective therapies against BCa.
- | Journal: Down-regulated ciRS-7/up-regulated miR-7 axis aggravated cartilage degradation and autophagy defection by PI3K/AKT/mTOR activation mediated by IL-17A in osteoarthritis. (Pubmed Central) - Apr 20, 2021
miR-7-siRNA-expressing lentiviruses alleviated surgical resection-induced cartilage destruction of OA mice, whereas miR-7 mimics worsened the effects. Thus, these findings revealed that the mechanism of the ciRS-7/miR-7 axis involved regulating OA progression and provided valuable directions for OA treatment.
- | Journal: Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees. (Pubmed Central) - Apr 20, 2021
Thus, these findings revealed that the mechanism of the ciRS-7/miR-7 axis involved regulating OA progression and provided valuable directions for OA treatment. The phenomenon that the enrichments of germline SNPs in the PI3K/AKT pathway might be a major predictor of familial susceptibility to lung cancer.
- | Journal: Daturataturin A, a withanolide in Datura metel L., induces HaCaT autophagy through the PI3K-Akt-mTOR signaling pathway. (Pubmed Central) - Apr 20, 2021
DTA also negatively regulated inflammation through the activation of autophagy. This may be one of the mechanisms underlying the action of Datura metel L. preparation used for the treatment of psoriasis.
- | Journal: FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K. (Pubmed Central) - Apr 20, 2021
In summary, FoxO1 contributes to exercise-induced hypertrophy. This has important implications when considering FoxO1 as a target for treating the diseased heart.
- | perifosine (D21266) / AEterna Zentaris
Journal, IO biomarker: Akt Inhibition Enhanced the Growth Inhibition Effects of Low-Dose Heavy-Ion Radiation via the PI3K/Akt/p53 Signaling Pathway in C6 Glioblastoma Cells. (Pubmed Central) - Apr 20, 2021
The growth inhibition effects of low-dose heavy-ion irradiation were not substantial in C6 cells, and Akt inhibition induced by perifosine enhanced the growth inhibition effects via proliferation inhibition, apoptosis, and oxidative stress. Akt inhibition enhanced the effects of heavy-ion radiation, and the PI3K/Akt/p53 signaling pathway may be a critical component involved in the process.
- |||||||||| parsaclisib (INCB50465) / Incyte
New P3 trial, Combination therapy: CITADEL-310: A Study of Parsaclisib, a PI3K? Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 18, 2021
P3, N=516, Not yet recruiting, Sponsor: Incyte Corporation
- ||| Bravo 👏🏻 to @JackWestMD for calling it how it is... in my view CLL and PI3K space is the worst offender for this @VPrasadMDMPH (Twitter) - Apr 18, 2021
- | Journal: MicroRNA-363-3p promotes apoptosis in response to cadmium-induced renal injury by down-regulating phosphoinositide 3-kinase expression. (Pubmed Central) - Apr 18, 2021
Also, we determined that miR-363-3p increase is associated with phosphoinositide 3-kinase (PI3K) down-regulation and the suppressed proliferation and enhanced apoptosis of renal tubule epithelial cells. The obtained results suggest miR-363-3p involvement in the pathophysiology of Cd-induced renal injury in humans and maybe considered for possible interventional therapeutic strategies for Cd-associated kidney damage.
- ||| Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer https://t.co/wEkldbUkbS (Twitter) - Apr 17, 2021
- | Journal: Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer. (Pubmed Central) - Apr 17, 2021
We found that cotargeting PI3K/mTOR and bromodomain and extra-terminal domain can suppress activation of many oncogenic kinases involved in resistance to the PI3K/mTOR inhibition, induce cell death in vitro and tumor regression in vivo, and further prolong the survival of xenograft models. Our findings provide a rationale for a novel therapeutic strategy to overcome resistance to the PI3K/mTOR inhibitors in CRC.
- | Journal: Gypenoside Inhibits Endothelial Cell Apoptosis in Atherosclerosis by Modulating Mitochondria through PI3K/Akt/Bad Pathway. (Pubmed Central) - Apr 17, 2021
Moreover, gypenoside downregulated mitochondrial fission and fusion proteins, mitochondrial energy-related proteins in the mouse aorta. In conclusion, this study demonstrated a new function of gypenoside in endothelial apoptosis and suggested a therapeutic potential of gypenoside in atherosclerosis associated with apoptosis by modulating mitochondrial function through the PI3K/Akt/Bad pathway.
- | Journal: OSCC Exosomes Regulate miR-210-3p Targeting EFNA3 to Promote Oral Cancer Angiogenesis through the PI3K/AKT Pathway. (Pubmed Central) - Apr 17, 2021
In conclusion, miR-210-3p was more overexpressed in OSCC tissues than in the JCT. The exosomes secreted by OSCC cells were able to upregulate miR-210-3p expression and reduce ephrinA3 expression in HUVECs and promoted tube formation through the PI3K/AKT signaling pathway.
- | Journal: Silencing ATG6 and PI3K accelerates petal senescence and reduces flower number and shoot biomass in petunia. (Pubmed Central) - Apr 17, 2021
Our study also found that autophagy genes potentially influence the transcriptional regulation of metacaspases and ethylene biosynthetic genes during petal senescence. The results of this project will be fundamental for future studies of petal senescence and will provide genetic information for future crop improvement.
- | quercetin (LY294002) / Eli Lilly, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal: Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells. (Pubmed Central) - Apr 17, 2021
However, and in contrast with the findings of others, we detected no synergistic effect between olaparib and oxaliplatin, and we found that the Akt pathway inhibitor augmented the cytostatic properties of the platinum compound and/or prevented the cytoprotective effects of PARP inhibition. Our results suggest that, at therapeutically relevant concentrations, the cytotoxicity of the platinum compound dominated over that of the PARP inhibitor and the PI3K inhibitor, even though a regression-based model could have indicated an overall synergy at lower and/or higher concentrations.
- | Journal: The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer-A Preliminary Study. (Pubmed Central) - Apr 17, 2021
It was also indicated that in the group of patients with mutations in the area of the PIK3CA and AKT1 genes, the PIK3CA gene expression level is statistically significantly lower than in the group without mutations. According to our knowledge, we demonstrate, for the first time, that there is a very strong positive correlation between the levels of AKT1 and mTOR gene expression in the case of patients with mutations and without mutations.
- |||||| Ukoniq (umbralisib) / TG Therap
FDA event: On Monday, listen to @DrNabilSaba, MD, FACP, of @WinshipAtEmory, discuss nasopharyngeal carcinoma and ongoing studies. On Thursday, hear from @JmPagelMD, of @Swedish, who spoke about the evolving role of PI3K inhibitors in lymphoma in light of the @US_FDA approval of umbralisib. (Twitter) - Apr 16, 2021
- ||||| VS-5584 / Verastem, VS-6766 / Verastem
I'd like to see @VerastemOncolog @danwpaterson not to shy away to try vs-5584 (pi3k mTORc1/2) vs. Everolimus in Vs-6766 combo. Vs-5584 is very intriguing compound! FAKi will work in some indications, but mTOR may expand the #MAPK #cancer platform. https://t.co/wEVbnkeZ5C (Twitter) - Apr 16, 2021
- | Journal: MicroRNA-196a promotes cell proliferation and inhibits apoptosis in human ovarian cancer by directly targeting DDX3 and regulating the PTEN/PI3K/AKT signaling pathway. (Pubmed Central) - Apr 16, 2021
Taken together, this confirmed an association between DDX3 and miR‑196a in ovarian cancer, and showed that miR‑196a promoted the proliferation of ovarian cancer cells and attenuated apoptosis by downregulating the expression of DDX3 through the PTEN/PI3K/AKT pathway. Overall, the results of the present study suggested that DDX3 could be a novel target for ovarian cancer treatment.
- || Piqray (alpelisib) / Novartis
PK/PD data, Journal: A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. (Pubmed Central) - Apr 16, 2021
The BYLieve trial suggests alpelisib-fulvestrant benefit after progression on CDK 4/6 inhibitors. The identification of patients that are likely to benefit the most from PI3K inhibitors is still eagerly sought.
- | Journal: Fargesin Inhibits EGF-Induced Cell Transformation and Colon Cancer Cell Growth by Suppression of CDK2/Cyclin E Signaling Pathway. (Pubmed Central) - Apr 16, 2021
Simultaneously, the suppression of CDK2/cyclin E and induction of p21 were correlated with Rb phosphorylation and c-Myc suppression. Taken together, we conclude that fargesin-mediated c-Myc suppression inhibits EGF-induced cell transformation and colon cancer cell colony growth by the suppression of retinoblastoma (Rb)-E2F and CDK/cyclin signaling pathways, which are mainly regulated by MAPK and PKB signaling pathways.
- | PI-103 / Roche
Journal, Combination therapy: Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. (Pubmed Central) - Apr 16, 2021
Doxorubicin with RIDR-PI-103 inhibited p-AktS473, upregulated p-CHK1/2 and p-P53. PK studies showed that ~200 ng/mL (0.43 µM) RIDR-PI-103 is achievable in mice plasma with an initial dose of 20 mg/kg and a 10 h T. (4) The prodrug RIDR-PI-103 could be a potential therapeutic for treatment of breast cancer patients.
- | Journal: Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways. (Pubmed Central) - Apr 15, 2021
PK studies showed that ~200 ng/mL (0.43 µM) RIDR-PI-103 is achievable in mice plasma with an initial dose of 20 mg/kg and a 10 h T. (4) The prodrug RIDR-PI-103 could be a potential therapeutic for treatment of breast cancer patients. We demonstrated, for the first time, that erianin inhibited the proliferation, migration, invasion and induced the apoptosis of HCC through PI3K/Akt, p38 and ERK MAPK signaling pathway, indicating that erianin is a promising agent for the HCC treatment.
- | Journal, Combination therapy, PARP Biomarker, IO biomarker: Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. (Pubmed Central) - Apr 15, 2021
We report ongoing clinical trials involving these agents, either in monotherapy or in combination with other compounds, highlighting the dynamic scenario of metastatic urothelial carcinoma treatment. Several challenges need to be faced in the development of new potential therapeutic strategies, such has inter/intratumoral heterogeneity and the lack of validated biomarkers.
- | Journal, IO biomarker: MiR-25-3p targets PTEN to regulate the migration, invasion, and apoptosis of esophageal cancer cells via the PI3K/AKT pathway. (Pubmed Central) - Apr 15, 2021
Several challenges need to be faced in the development of new potential therapeutic strategies, such has inter/intratumoral heterogeneity and the lack of validated biomarkers. MiR-25-3p targeted PTEN to promote the migration and invasion, and inhibit apoptosis of EC cells via the PI3K/AKT pathway, which might provide a new therapeutic target for EC treatment.
- | Journal, IO biomarker: Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion. (Pubmed Central) - Apr 15, 2021
Collectively, ADAMTS9-AS2 inhibited liver cancer cell proliferation, migration and invasion via inhibiting the PI3K/AKT/mTOR signaling pathway. The present study provided a novel insight into the role of ADAMTS9-AS2 in liver cancer.
- sirolimus / Generic mfg.
[VIRTUAL] NOVEL MUTATIONS AND ROLE OF MOLECULARLY TARGETED THERAPY IN PEDIATRIC SPINDLE CELL RHABDOMYOSARCOMA () - Apr 14, 2021 - Abstract #ASPHO2021ASPHO_279;
While LY3023414 and rapamycin biochemically inhibited the PI3K/AKT pathway significantly, single drug agents did not result in cell death. However, combination therapy involving LY3023414 with doxorubicin and rapamycin with vincristine showed synergistic effect.
- paclitaxel / Generic mfg.
[VIRTUAL] CHEMOTHERAPY-INDUCED SENSORY PERIPHERAL NEUROPATHY: THE ROLE OF PHOSPHOINOSITIDE 3-KINASE SIGNALING () - Apr 14, 2021 - Abstract #ASPHO2021ASPHO_271;
As other studies suggest, PIPN-related findings might extend to vinca alkaloids: microtubule stabilizers and destabilizers cause mitotic arrest with common downstream effects on gene expression and effector molecules. Future experiments and validation of preliminary data are necessary.
- || Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health
Clinical, Journal: Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. (Pubmed Central) - Apr 14, 2021
PIK3CA mutations were detected in more than one third of AR+ TNBC from patients (38%), and only 10% of AR-negative TNBC. Our results for PDX models of LAR TNBC resistant to enzalutamide indicate that PIK3CA and AKT1 are potential therapeutic targets.
- | Journal, IO biomarker: Polyphyllin I Promoted Melanoma Cells Autophagy and Apoptosis via PI3K/Akt/mTOR Signaling Pathway. (Pubmed Central) - Apr 14, 2021
Meanwhile, Polyphyllin I treatment suppressed the development of melanoma in vivo. Therefore, Polyphyllin I possibly is a promising molecular targeted agent used in melanoma therapy.
- | Journal: Advanced Glycation End Products Induce Proliferation and Migration of Human Aortic Smooth Muscle Cells through PI3K/AKT Pathway. (Pubmed Central) - Apr 14, 2021
Additionally, the phosphorylation of AKT was reduced when the receptor of advanced glycation end product (RAGE) gene was silenced by lentivirus transfection, which led to a concomitant reduction of the expression of proliferation and migration-related proteins. These data indicate that AGEs may activate the PI3K/AKT pathway through RAGE and thus facilitate the proliferation and migration of HASMCs.
- | ketamine / Generic mfg., sirolimus / Generic mfg.
Journal: The involvement of PI3K/Akt/mTOR/GSK3β signaling pathways in the antidepressant-like effect of AZD6765. (Pubmed Central) - Apr 14, 2021
In this context, we demonstrated that a single administration of AZD6765 (1 mg/kg, i.p.) was able to induce an antidepressant-like effect in mice submitted to tail suspension test (TST), an effect reversed by LY294002 (a reversible PI3K inhibitor, 10 nmol/site, i.c.v.), wortmannin (an irreversible PI3K inhibitor, 0.1 μg/site, i.c.v.) and rapamycin (a selective mTOR inhibitor, 0.2 nmol/site, i.c.v.)...In addition, a single administration of AZD6765 (1 mg/kg, i.p.) or ketamine (1 mg/kg, i.p.) reversed the depressive-like behavior induced by chronic unpredictable stress (CUS). Altogether, the results provide evidence for the fast-acting antidepressant profile of AZD6765, by a mechanism likely dependent on PI3K/Akt/mTOR/GSK3β.
- || Clinical, Review, Journal: A Case for Phosphoinositide 3-Kinase-Targeted Therapy for Infectious Disease. (Pubmed Central) - Apr 14, 2021
In this review, we briefly highlight the development and applications of PI3K inhibitors and summarize data supporting the concept that PI3Kδ inhibitors initially developed for oncology have immune regulatory potential that could be exploited to improve the control of some infectious diseases. This repurposing of existing kinase inhibitors could lay the foundation for alternative infectious disease therapy using available therapeutic agents.
- | Journal, IO biomarker: Farnesoid X receptor promotes renal ischaemia-reperfusion injury by inducing tubular epithelial cell apoptosis. (Pubmed Central) - Apr 14, 2021
These results established the pivotal importance of FXR inactivation in tubular epithelial cells after I/R injury. FXR may promote the apoptosis of renal tubular epithelial cells by inhibiting PI3k/Akt-mediated Bad phosphorylation to cause renal I/R damage.
- | quercetin (LY294002) / Eli Lilly
Preclinical, Journal: XQ-1H promotes cerebral angiogenesis via activating PI3K/Akt/GSK3β/β-catenin/VEGF signal in mice exposed to cerebral ischemic injury. (Pubmed Central) - Apr 14, 2021
Mechanism studies revealed that XQ-1H exerted angiogenesis promoting effect via the PI3K/Akt/GSK3β/β-catenin/VEGF signal pathway, which was reversed by LY294002 (the specific inhibitor of PI3K/Akt). In conclusion, XQ-1H exerts angiogenetic effect both in vivo and in vitro, which is a potential agent against ischemic stroke during chronic phase.
- | quercetin (LY294002) / Eli Lilly, PRI-724 / PRISM Pharma, Ohara Pharma
Journal: WISP1 Protects Against Chondrocyte Senescence and Apoptosis by Regulating αvβ3 and PI3K/Akt Pathway in Osteoarthritis. (Pubmed Central) - Apr 14, 2021
These data strongly suggest that WISP1 can protect against the senescence and apoptosis of chondrocytes via modulating the αvβ3 receptor and PI3K/Akt signaling pathway within OA. Therefore, the development of specific activators of WISP1 may present the value of an underlying OA treatment.
- | Journal: SCARF1 promotes M2 polarization of Kupffer cells via calcium-dependent PI3K-AKT-STAT3 signalling to improve liver transplantation. (Pubmed Central) - Apr 14, 2021
Therefore, the development of specific activators of WISP1 may present the value of an underlying OA treatment. SCARF1 promotes the M2 polarization of KCs by promoting phagocytosis through the calcium-dependent PI3K-AKT-STAT3 signalling pathway.
- | Journal: Demethoxycurcumin Suppresses Proliferation, Migration, and Invasion of Human Brain Glioblastoma Multiforme GBM 8401 Cells via PI3K/Akt Pathway. (Pubmed Central) - Apr 14, 2021
DMC inhibited cancer cell migration and invasion through inhibition of PI3K/Akt and NF-κB signaling pathways in GBM 8401 cells. We suggest that DMC may be used as a novel anti-metastasis agent for the treatment of human glioblastoma cancer in the future.
- | Preclinical, Journal: [Retracted] Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. (Pubmed Central) - Apr 14, 2021
The Editor regrets any inconvenience that has been caused to the readership of the Journal. [the original article was published in Molecular Medicine Reports 11: 931‑939, 2015; DOI: 10.3892/mmr.2014.2819].
- ||| Aliqopa (copanlisib) / Bayer, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, P3 data, Journal: Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. (Pubmed Central) - Apr 14, 2021
P3
Copanlisib plus rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma compared with placebo plus rituximab. To our knowledge, copanlisib is the first PI3K inhibitor to be safely combined with rituximab and the first to show broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin lymphoma.